Anvisa Approves Medicine to Treat Schistosomiasis in Children
8 Articles
8 Articles
The drug Farmanguinhos Arpraziquantel (arpraziquantel), produced by Fiocruz, was approved by the National Agency for Health Surveillance (Anvisa). The drug is indicated for the treatment of schistosomiasis, a disease caused by the parasite Schistosome mansoni or Schistosome haematobium, in children from 3 months to 6 years. "When ingested, the arpraziquantel is absorbed by the worms in the patient's blood vessels and causes muscle spasms and par…
Anvisa approved the registration of Farmanguinhos Arpraziquantel, a medicine to treat schistosomiasis in children from 3 months to 6 years, a group until then outside the pediatric indication. At least 253.7 million people needed preventive treatment against the disease in the world in 2024, according to the WHO.
Arpraziquantel is indicated for children aged 3 to 6 years and can destroy the worms that cause the disease
The disease is acquired by contact with fresh water that contains caramuli infected by worms causing
Tribuna Online
Agence Nacional de Vigilância Sanitária (Anvisa) Photo: Marcelo Camargo/Agência Brasil The Agence Nacional de Vigilância Sanitária (Anvisa) approved on Wednesday (30) the registration of the drug Farmanguinhos Arpraziquantel, indicated for the treatment of schistosomosis caused by the parasite Schistosome mansoni or Schistosome haematobium in children from 3 months to 6 years.The resolution was published in the Official Journal of the Union.In a…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
